FDA Approves Gilead Product Yescarta For Additional Kinds Of Lymphoma

FDA批准Gilead产品Yescarta用于其他种类的淋巴瘤

2021-03-12 07:00:18 RTTNews

本文共225个字,阅读需1分钟

The Food and Drug Administration has given accelerated approval to Yescarta, the chimeric antigen receptor from Gilead Sciences . A form of T-cell therapy, Yescarta has now been approved to treat adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. The approval was based on results of a recent study in which 91 percent of patients with FL responded positively to the treatment. Yescarta had already been approved for adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. For comments and feedback contact: editorial@rttnews.com
食品和药物管理局已经加速批准了来自吉利德科学的嵌合抗原受体Yescarta。 Yescarta是T细胞治疗的一种形式,目前已被批准用于治疗经过两种或两种以上系统治疗后复发或难治性滤泡性淋巴瘤(FL)的成人患者。 这项批准是基于最近一项研究的结果,91%的FL患者对该治疗反应积极。 Yescarta已经被批准用于经过两种或两种以上系统治疗的复发或难治性大B细胞淋巴瘤的成人患者。 如需评论和反馈,请联系:editorial@rttnews.com

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文